{"nctId":"NCT00424372","briefTitle":"A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia","startDateStruct":{"date":"2007-01-12","type":"ACTUAL"},"conditions":["Neuralgia, Postherpetic"],"count":126,"armGroups":[{"label":"pregabalin","type":"EXPERIMENTAL","interventionNames":["Drug: pregabalin"]}],"interventions":[{"name":"pregabalin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who completed the 13-week treatment of postherpetic neuralgia in Study A0081120.\n* Patients must be able to understand and cooperate with study procedures and have signed a written informed consent prior to entering the study.\n\nExclusion Criteria:\n\n* Patients who experienced serious adverse events in the preceding study (A0081120) that were determined by the investigator or the study sponsor to be causally related to the study medication.\n* Patients exhibiting treatment non-compliance in the preceding study (A0081120)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Summary of Adverse Events","description":"Number of subjects with all causality adverse events, serious adverse events, severe adverse events, adverse events resulted in discontinuation, dose reduced or temporary discontinuation. Subjects are counted only once per treatment in each row.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Short-Form McGill Pain Questionnaire the Efficacy of Change: Sensory Score","description":"Score ranges: 0-33. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \\<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"5.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"5.9"}]}]}]},{"type":"SECONDARY","title":"Short-Form McGill Pain Questionnaire the Efficacy of Change: Affective Score","description":"Score ranges: 0-12. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \\<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"3.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"2.8"}]}]}]},{"type":"SECONDARY","title":"Short-Form McGill Pain Questionnaire the Efficacy of Change: Total Score","description":"Score ranges: 0-45. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \\<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":"9.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"9.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"8.4"}]}]}]},{"type":"SECONDARY","title":"Short-Form McGill Pain Questionnaire the Efficacy of Change: Present Pain Intensity","description":"Score ranges: 0-5. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \\<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Short-Form McGill Pain Questionnaire the Efficacy of Change: Visual Analog Scale","description":"Ranges: 0-100 mm. Larger scale indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \\<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":"19.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":"22.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":"25.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.3","spread":"23.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":126},"commonTop":["Dizziness","Nasopharyngitis","Oedema peripheral","Somnolence","Weight increased"]}}}